Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Candel Therapeutics (CADL) Change in Account Payables (2020 - 2023)

Candel Therapeutics' Change in Account Payables history spans 4 years, with the latest figure at $172000.0 for Q4 2023.

  • For Q4 2023, Change in Account Payables rose 131.62% year-over-year to $172000.0; the TTM value through Dec 2023 reached $45000.0, up 103.71%, while the annual FY2024 figure was -$185000.0, 511.11% down from the prior year.
  • Change in Account Payables for Q4 2023 was $172000.0 at Candel Therapeutics, up from -$214000.0 in the prior quarter.
  • Across five years, Change in Account Payables topped out at $818000.0 in Q3 2020 and bottomed at -$579000.0 in Q1 2022.
  • The 4-year median for Change in Account Payables is $43500.0 (2023), against an average of -$15642.9.
  • The largest annual shift saw Change in Account Payables surged 223.61% in 2021 before it tumbled 434.68% in 2022.
  • A 4-year view of Change in Account Payables shows it stood at -$538000.0 in 2020, then soared by 223.61% to $665000.0 in 2021, then plummeted by 181.8% to -$544000.0 in 2022, then soared by 131.62% to $172000.0 in 2023.
  • Per Business Quant, the three most recent readings for CADL's Change in Account Payables are $172000.0 (Q4 2023), -$214000.0 (Q3 2023), and -$62000.0 (Q2 2023).